Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HUM
stocks logo

HUM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
32.08B
+9.81%
-3.904
+80.76%
35.36B
+10.12%
10.701
-7.59%
36.19B
+11.74%
5.228
-16.61%
Estimates Revision
The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by -17.83%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.76%
In Past 3 Month
Stock Price
Go Down
down Image
-17.83%
In Past 3 Month
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 293.81 USD with a low forecast of 231.00 USD and a high forecast of 341.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 293.81 USD with a low forecast of 231.00 USD and a high forecast of 341.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
9 Hold
1 Sell
Moderate Buy
Current: 253.020
sliders
Low
231.00
Averages
293.81
High
341.00
Current: 253.020
sliders
Low
231.00
Averages
293.81
High
341.00
Barclays
Andrew Mok
Equal Weight
downgrade
$245 -> $234
2025-11-25
Reason
Barclays
Andrew Mok
Price Target
$245 -> $234
2025-11-25
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Humana to $234 from $245 and keeps an Equal Weight rating on the shares. If company "executes flawlessly," $14 of earnings per share next year is possible, the analyst tells investors in a research note. However, the firm says Humana's "execution risk is real." It models break-even individual Medicare Advantage margins and $11 in EPS.
Wells Fargo
Stephen Baxter
Overweight
downgrade
$347 -> $290
2025-11-10
Reason
Wells Fargo
Stephen Baxter
Price Target
$347 -> $290
2025-11-10
downgrade
Overweight
Reason
Wells Fargo analyst Stephen Baxter lowered the firm's price target on Humana to $290 from $347 and keeps an Overweight rating on the shares. The firm is also lowering estimates on refined star rating headwind given clarity on VBC / Group MA dynamics.
Truist
Hold
downgrade
$300 -> $285
2025-11-10
Reason
Truist
Price Target
$300 -> $285
2025-11-10
downgrade
Hold
Reason
Truist lowered the firm's price target on Humana to $285 from $300 and keeps a Hold rating on the shares. The firm is citing the company's Q3 results along with its "more conservative" margin assumptions, the analyst tells investors in a research note.
Deutsche Bank
George Hill
Hold
downgrade
$250 -> $231
2025-11-07
Reason
Deutsche Bank
George Hill
Price Target
$250 -> $231
2025-11-07
downgrade
Hold
Reason
Deutsche Bank analyst George Hill lowered the firm's price target on Humana to $231 from $250 and keeps a Hold rating on the shares.
Mizuho
Outperform -> NULL
downgrade
$345 -> $310
2025-11-07
Reason
Mizuho
Price Target
$345 -> $310
2025-11-07
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Humana to $310 from $345 and keeps an Outperform rating on the shares.
Goldman Sachs
Scott Fidel
initiated
$235
2025-10-14
Reason
Goldman Sachs
Scott Fidel
Price Target
$235
2025-10-14
initiated
Reason
Goldman Sachs analyst Scott Fidel initiated coverage of Humana with a Sell rating and $235 price target. The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Humana Inc (HUM.N) is 18.86, compared to its 5-year average forward P/E of 18.71. For a more detailed relative valuation and DCF analysis to assess Humana Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
18.71
Current PE
18.86
Overvalued PE
21.06
Undervalued PE
16.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.58
Undervalued EV/EBITDA
10.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.49
Current PS
0.00
Overvalued PS
0.65
Undervalued PS
0.33
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HUM News & Events

Events Timeline

(ET)
2025-12-01
12:11:00
Major Averages Decline as Investors Await Economic Data and Powell's Speech
select
link
2025-12-01
07:40:00
Humana Reaffirms 2025 EPS Guidance of Approximately $12.26
select
2025-11-25 (ET)
2025-11-25
11:36:38
Humana plans to challenge decision supporting reductions in Medicare Star bonuses, according to Bloomberg.
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
02:23 AMSeekingAlpha
Humana and Mark Cuban May Collaborate on Pharmacy Venture

  • Partnership Development: Humana and Mark Cuban's Cost Plus Drugs are exploring a partnership aimed at simplifying the drug supply chain and creating direct-to-employer programs.

  • Cost Plus Drugs' Mission: The company seeks to disrupt pharmacy benefit managers (PBMs) by eliminating rebates and spread pricing, allowing patients to access medications at lower costs directly.

  • Political Context: Former President Trump has criticized PBMs, referring to them as "drug middlemen," which has prompted the PBM industry to consider reforms in response to regulatory scrutiny.

  • Humana's Recent Activities: Humana has been active in the healthcare sector, including presenting at conferences and addressing financial challenges related to rising medical costs and Medicare Star bonuses.

[object Object]
Preview
7.0
12-03Globenewswire
Humana Faces Allegations of $250 Million Illegal Kickbacks to Insurance Brokers
  • Kickback Allegations: Berman Tabacco is investigating whether Humana paid illegal kickbacks totaling up to $250 million to insurance brokers between 2016 and 2021, which could severely impact the company's reputation and shareholder confidence.
  • Executive Involvement: The complaint alleges that senior executives at Humana were personally involved in the kickback scheme, which not only raises potential legal liabilities but also questions regarding corporate governance among shareholders.
  • Stock Price Reaction: Following the filing of the complaint, Humana's shares declined approximately 3%, indicating market sensitivity to these allegations and investor concerns about the company's future outlook.
  • Board Investigation: Berman Tabacco is examining whether Humana's board of directors had a role in this scheme, and if confirmed, it could lead to further legal repercussions and shareholder lawsuits.
[object Object]
Preview
6.5
12-03NASDAQ.COM
Is the Decline in UnitedHealth's Valuation and Asset Sales a Genuine Buying Opportunity?

  • Current Valuation and Market Position: UnitedHealth Group (UNH) is trading at 18.48X forward earnings, slightly below its five-year median but above the industry average, reflecting a premium for its scale and stability. Despite a 7.3% gain over the past six months, concerns about margin pressure and medical cost growth persist.

  • Membership and Growth Outlook: The company anticipates a decline in Medicare Advantage enrollment and challenges in its commercial segment, with full margin normalization not expected until 2027. However, management is optimistic about margin recovery through disciplined pricing and operational improvements.

  • Regulatory Scrutiny and Operational Changes: UnitedHealth faces ongoing regulatory investigations regarding its Medicare billing and pharmacy operations, adding uncertainty to its outlook. The company is also exiting Latin America to streamline operations, having sold its final South American operation.

  • Long-Term Growth Potential: Despite near-term challenges, UnitedHealth's scale and diversified model position it well for long-term growth driven by rising healthcare spending and demographic trends. Analysts project earnings stabilization and growth by 2026, maintaining a cautious but positive investment outlook.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Humana Inc (HUM) stock price today?

The current price of HUM is 253.02 USD — it has decreased -1.52 % in the last trading day.

arrow icon

What is Humana Inc (HUM)'s business?

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

arrow icon

What is the price predicton of HUM Stock?

Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 293.81 USD with a low forecast of 231.00 USD and a high forecast of 341.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Humana Inc (HUM)'s revenue for the last quarter?

Humana Inc revenue for the last quarter amounts to 32.65B USD, increased 11.06 % YoY.

arrow icon

What is Humana Inc (HUM)'s earnings per share (EPS) for the last quarter?

Humana Inc. EPS for the last quarter amounts to 1.61 USD, decreased -59.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Humana Inc (HUM)'s fundamentals?

The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by -17.83%.
arrow icon

How many employees does Humana Inc (HUM). have?

Humana Inc (HUM) has 65680 emplpoyees as of December 05 2025.

arrow icon

What is Humana Inc (HUM) market cap?

Today HUM has the market capitalization of 30.43B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free